Pattern of Liver Disease Following High-Dose Cytosine Arabinoside (HDARAC) Therapy in Children with Acute Myeloid Leukemia |
| |
| Authors: | Anna Locasciulli Cornelio Uderzo Ambrogina Pirola Giuseppe Masera Bernard Portmann Alfredo Alberti |
| |
| Affiliation: | a Clinica Pediatrica Universita's di Milano, Ospedale “S. Gerardo”, Monza, Milan, Italyb Liver Unit, King's College Hospital and Medical School, London, UKc Istituto di Medicina Clinica, Clinica Medica II Universita's di, Padova, Italy |
| |
| Abstract: | ![]()
The occurrence of liver disease and its relation to HBV markers were investigated in ten children with AML who were given HDARAC as late consolidation therapy. None of them developed jaundice or biochemical evidence of cholestasis. During therapy, SGPT values were normal in 5/10 patients, while in the other 5 a sharp increase was noted. These enzyme elevations followed an unusual timing, peaking just before each infusion of HDARAC. Evidence of long-lasting hepatocellular necrosis after therapy withdrawal was found in 8/8 cases. One child died of fulminant type B hepatitis and HBsAg positivity was found in 2/10 patients during therapy and 3/8 after withdrawal of the drug. Three children developed HBV antibodies during the observation period. We conclude that the use of HDARAC in childhood leukemia is not associated with major evidence of direct drug hepatotoxicity while it clearly affects the natural outcome of viral hepatitis |
| |
| Keywords: | Ara-C HBV infection acute myeloid leukemia |
| 本文献已被 InformaWorld 等数据库收录！ |
|
